Brokerages Expect MacroGenics Inc (MGNX) to Announce -$0.95 EPS

Brokerages predict that MacroGenics Inc (NASDAQ:MGNX) will report earnings of ($0.95) per share for the current quarter, Zacks reports. Five analysts have issued estimates for MacroGenics’ earnings, with estimates ranging from ($1.33) to ($0.38). MacroGenics reported earnings per share of ($1.03) during the same quarter last year, which indicates a positive year over year growth rate of 7.8%. The business is expected to report its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that MacroGenics will report full year earnings of ($3.70) per share for the current fiscal year, with EPS estimates ranging from ($5.01) to ($2.18). For the next fiscal year, analysts anticipate that the company will post earnings of ($4.21) per share, with EPS estimates ranging from ($5.47) to ($2.50). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow MacroGenics.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.04). MacroGenics had a negative net margin of 256.47% and a negative return on equity of 57.65%. The business had revenue of $9.66 million during the quarter, compared to analysts’ expectations of $11.46 million.

A number of research firms recently weighed in on MGNX. ValuEngine raised shares of MacroGenics from a “hold” rating to a “buy” rating in a report on Tuesday, May 7th. Zacks Investment Research lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, March 1st. HC Wainwright set a $39.00 target price on shares of MacroGenics and gave the company a “buy” rating in a report on Wednesday, February 20th. Nomura raised their target price on shares of MacroGenics from $41.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, February 7th. Finally, Wedbush lowered shares of MacroGenics from an “outperform” rating to a “neutral” rating in a report on Thursday, February 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $31.98.

Shares of MGNX stock traded up $0.83 on Friday, reaching $18.34. The company’s stock had a trading volume of 2,277,515 shares, compared to its average volume of 875,104. MacroGenics has a 1 year low of $9.87 and a 1 year high of $32.32. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.47 and a current ratio of 6.47. The firm has a market cap of $895.18 million, a PE ratio of -4.38 and a beta of 2.90.

In related news, SVP Eric Blasius Risser sold 3,000 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $18.38, for a total value of $55,140.00. Following the completion of the sale, the senior vice president now directly owns 33,806 shares in the company, valued at $621,354.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.88% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace North America L.P. bought a new stake in MacroGenics in the first quarter worth $59,000. Pearl River Capital LLC bought a new stake in MacroGenics in the first quarter worth $74,000. NumerixS Investment Technologies Inc bought a new stake in MacroGenics in the first quarter worth $74,000. Marshall Wace LLP bought a new stake in MacroGenics in the first quarter worth $80,000. Finally, Bank of Montreal Can lifted its position in MacroGenics by 804.2% in the first quarter. Bank of Montreal Can now owns 5,000 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 4,447 shares during the last quarter. Institutional investors own 90.64% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Read More: Market Capitalization

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.